12月29日 - ** Ultragenyx Pharmaceutical RARE.O股价盘前大跌42.5%至19美元
** RARE称 (link)，其治疗一种遗传性骨病的实验药物在后期研究中没有达到主要目标。
** 这种名为setrusumab的药物是为 成骨不全症患者 开发的，成骨不全症是一种导致骨骼变脆的罕见遗传性疾病。
** 虽然在减少骨折方面的研究没有达到统计学意义，但两项研究都显示骨矿物质密度有了明显改善，而骨矿物质密度是衡量骨骼强度的一个关键指标。
** 截至上一交易日收盘，股价累计下跌 18.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.